국소 분절 사구체 경화증(FSGS) 치료제 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 연간 평균 성장률(CAGR) 9.8%로 성장할 전망이며, 248억 7,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 연구개발비 및 헬스케어 지출의 증가, 의식 및 진단의 고조, 고령화, 정부의 대처, 자금 조달에 기인할 것으로 보입니다. 예측 기간 주요 동향으로는 신약개발 기술 진보, 임상시험 파이프라인 확대, 치료에 대한 상환 개선, 기업의 연구시설 확대 등을 들 수 있습니다.
신장 감염의 이환율 증가는 가까운 미래에 국소 분절 사구체 경화증(FSGS) 치료제 시장의 확대를 견인 할 전망입니다. 신장 감염은 신우 신염으로도 알려져 있으며 한쪽 또는 양쪽 신장을 침범하는 요로 감염(UTI)의 심각한 형태입니다. 신장 질환을 치료하기 위해 개발된 국소 분절 사구체 경화증(FSGS) 치료제는 병리학을 관리하고 신장 기능을 향상시키는 데 많은 이점을 제공합니다. 단백뇨를 감소시키고 신장 장애의 진행을 늦추며 궁극적으로 신장 질환을 앓고있는 환자의 QOL을 개선하여 이것을 달성합니다. 예를 들어, 2022년 7월 현재 미국 보건복지성의 일부문인 질병대책예방센터의 데이터에 따르면 미국 인구의 약 15%, 3700만 명이 신장병에 걸린 것으로 나타났습니다. 2021년에는 45-64세로 12%, 18-44세로 6%의 유병률이었습니다. 그 결과, 신장 감염증 증가가 국소 분절 사구체 경화증(FSGS) 시장 성장의 원동력이 되고 있습니다.
헬스케어 지출 증가는 향후 수년간 국소 분절 사구체 경화증(FSGS) 치료제 시장의 성장을 가속할 것으로 예상됩니다. 헬스케어 지출이란 특정 헬스케어 시스템이나 경제권에서 정해진 기간 내에 헬스케어 서비스나 관련 상품, 활동에 할당되는 총 자금을 말합니다. 헬스케어 지출 증가는 국소 분절 사구체 경화증(FSGS) 치료제 개발 및 가용성에 큰 이익을 가져올 수 있어 연구자금을 강화하고 임상시험을 촉진해 최종적으로 의약품 생산을 개선하기 위해서입니다. 예를 들면, 2023년 11월, 캐나다를 거점으로 하는 단체인 Canadian Institute for Health Information는, 캐나다에서 총 의료비는 2023년에 3,440억 달러에 달한 것으로 평가되었으며, 이는 1인당 8,740달러에 상당한다고 보고했습니다. 이는 2022년 의료비가 1.5% 증가에 그쳤던 전년과 비교하면 2.8% 증가해 헬스케어 투자 회복이 두드러짐을 부각시키고 있습니다. 따라서 의료비 증가가 국소 분절 사구체 경화증(FSGS) 치료제 시장 성장의 원동력이 되고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장-금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
- 세계의 국소 분절 사구체 경화증(FSGS) 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
- 최종 이용 산업의 분석
- 세계의 국소 분절 사구체 경화증(FSGS) 치료제 시장 : 성장률 분석
- 세계의 국소 분절 사구체 경화증(FSGS) 치료제 시장 실적 : 규모 및 성장(2019-2024년)
- 세계의 국소 분절 사구체 경화증(FSGS) 치료제 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
- 세계의 국소 분절 사구체 경화증(FSGS) 치료제 전체 시장 규모(TAM)
제6장 시장 세분화
- 세계의 국소 분절 사구체 경화증(FSGS) 치료제 시장 : 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 로스마피모드
- SHP-627
- 스파르센탄
- TM-5484
- 기타 유형
- 세계의 국소 분절 사구체 경화증(FSGS) 치료제 시장 : 치료별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 코르티코스테로이드
- 면역억제제
- 안지오텐신 전환효소(ACE) 억제제
- AR블로커
- 이뇨제
- 기타 치료법
- 세계의 국소 분절 사구체 경화증(FSGS) 치료제 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 오랄
- 비경구
- 세계의 국소 분절 사구체 경화증(FSGS) 치료제 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 병원
- 홈케어
- 전문 클리닉
- 기타 최종 사용자
제7장 지역별 및 국가별 분석
- 세계의 국소 분절 사구체 경화증(FSGS) 치료제 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 국소 분절 사구체 경화증(FSGS) 치료제 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
- 국소 분절 사구체 경화증(FSGS) 치료제 시장 : 경쟁 구도
- 국소 분절 사구체 경화증(FSGS) 치료제 시장 : 기업 프로파일
- Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- Johnson and Johnson Ltd. 개요, 제품 및 서비스, 전략 및 재무 분석
- F. Hoffmann-La Roche AG 개요, 제품 및 서비스, 전략 및 재무 분석
- Bayer AG 개요, 제품 및 서비스, 전략 및 재무 분석
- Novartis AG 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- Sanofi SA
- Bristol Myers Squibb Company
- AstraZeneca Plc
- Fresenius Kabi Ltd.
- GSK Plc
- Medtronic Plc.
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Astellas Pharma Inc.
- Otsuka Pharmaceutical Co. Ltd.
- Mylan NV
- B. Braun Melsungen AG
- Hikma Pharmaceuticals PLC
- Alexion Pharmaceuticals
- Wockhardt
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
- 국소 분절 사구체 경화증(FSGS) 치료제 시장 : 새로운 기회를 제공하는 국가(2029년)
- 국소 분절 사구체 경화증(FSGS) 치료제 시장 : 새로운 기회를 제공하는 부문(2029년)
- 국소 분절 사구체 경화증(FSGS) 치료제 시장 : 성장 전략(2029년)
제36장 부록
AJY
Focal segmental glomerulosclerosis (FSGS) is a rare kidney disease characterized by the development of scar tissue in the filters of the kidneys. Medications designed to treat and manage the progression of FSGS are referred to as focal segmental glomerulosclerosis drugs.
The primary focal segmental glomerulosclerosis drugs include losmapimod, SHP-627, sparsentan, tm-5484, and others. Losmapimod is an investigational drug belonging to the class of p38 mitogen-activated protein kinase (MAPK) inhibitors. Treatment options encompass corticosteroids, immunosuppressive drugs, ACE inhibitors, AR blockers, diuretics, and more, which can be administered through various routes, including oral and parenteral. These medications serve various end-users, such as hospitals, homecare services, specialty clinics, and more.
The focal segmental glomerulosclerosis drugs market research report is one of a series of new reports from The Business Research Company that provides focal segmental glomerulosclerosis drugs market statistics, including focal segmental glomerulosclerosis drugs industry global market size, regional shares, competitors with a focal segmental glomerulosclerosis drugs market share, detailed focal segmental glomerulosclerosis drugs market segments, market trends and opportunities and any further data you may need to thrive in the focal segmental glomerulosclerosis drugs industry. This focal segmental glomerulosclerosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The focal segmental glomerulosclerosis drugs market size has grown strongly in recent years. It will grow from $15.77 billion in 2024 to $17.08 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to increasing disease prevalence, growing demand for new treatments, growing interest from pharmaceutical sector, increasing government support.
The focal segmental glomerulosclerosis drugs market size is expected to see strong growth in the next few years. It will grow to $24.87 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to research and development expenditure, rising healthcare expenditure, growing awareness and diagnosis, aging population, government initiatives and funding. Major trends in the forecast period include technological advancements in drug discovery and development, expanding clinical trials pipeline, improved reimbursement for focal segmental glomerulosclerosis drugs treatments, expansion of corporate research facilities.
The increasing incidence of kidney infections is poised to drive the expansion of the focal segmental glomerulosclerosis (FSGS) drugs market in the foreseeable future. Kidney infections, also known as pyelonephritis, represent a severe form of urinary tract infection (UTI) that affects one or both kidneys. Focal segmental glomerulosclerosis (FSGS) drugs, designed for the treatment of kidney diseases, offer numerous advantages in managing the condition and enhancing kidney function. They achieve this by reducing proteinuria, slowing the progression of kidney damage, and ultimately improving the quality of life for patients suffering from kidney diseases. For example, as of July 2022, data from the Centers for Disease Control and Prevention, a division of the US Department of Health and Human Services, revealed that approximately 15% of the US population, equivalent to 37 million individuals, were afflicted by kidney disease. In 2021, the prevalence was 12% among individuals aged 45-64 and 6% among those between 18 and 44. Consequently, the increasing occurrence of kidney infections serves as a driving force behind the growth of the focal segmental glomerulosclerosis (FSGS) market.
The increasing healthcare expenditure is expected to drive the growth of the focal segmental glomerulosclerosis (FSGS) drugs market in the coming years. Healthcare expenditure refers to the total funds allocated for healthcare services and related goods and activities within a specific healthcare system or economy over a defined timeframe. Higher healthcare expenditures can significantly benefit the development and availability of drugs for focal segmental glomerulosclerosis (FSGS), as they enhance research funding and facilitate clinical trials, ultimately improving drug production. For example, in November 2023, the Canadian Institute for Health Information, a Canada-based organization, reported that total health spending in Canada is projected to reach $344 billion in 2023, which equates to $8,740 per person. This represents a 2.8% increase compared to the previous year, which experienced a growth of only 1.5% in health spending in 2022, highlighting a notable recovery in healthcare investment. Therefore, the rise in healthcare expenditures is a driving force behind the growth of the focal segmental glomerulosclerosis (FSGS) drugs market.
Prominent companies in the focal segmental glomerulosclerosis (FSGS) market are increasingly directing their efforts toward product development and innovation to deliver dependable solutions to their clientele and bolster their market standing. As an example, in February 2023, Travere Therapeutics, a biopharmaceutical firm headquartered in the United States, introduced FILSPARI for focal segmental glomerulosclerosis (FSGS), an FDA-approved oral medication. FILSPARI is designed to treat IgA nephropathy (IgAN) and represents the first non-immunosuppressive therapy aimed at reducing proteinuria in IgAN, a rare kidney disease. Furthermore, FILSPARI has received orphan drug designation in both the United States and Europe for the treatment of IgAN and focal segmental glomerulosclerosis (FSGS).
In October 2023, Amgen, a biotechnology company based in the U.S., completed the acquisition of Horizon Therapeutics plc for $27.8 billion. This acquisition aims to enhance Amgen's product portfolio, which includes essential medications such as Tepezza and Krystexxa, utilized in the treatment of rare inflammatory conditions. Horizon Therapeutics is also a U.S.-based biotechnology company specializing in drugs for focal segmental glomerulosclerosis.
Major companies operating in the focal segmental glomerulosclerosis drugs market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, Fresenius Kabi Ltd., GSK PLC, Medtronic Plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., B. Braun Melsungen AG, Hikma Pharmaceuticals PLC, Alexion Pharmaceuticals, Wockhardt, Travere Therapeutics, Aurinia Pharmaceuticals Inc., Omeros Corporation, Dimerix Ltd., Goldfinch Bio.
North America was the largest region in the focal segmental glomerulosclerosis drugs market in 2024. The regions covered in the focal segmental glomerulosclerosis (FSGS) drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
The countries covered in the focal segmental glomerulosclerosis (FSGS) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.
The focal segmental glomerulosclerosis (FSGS) drugs market consists of sales of rituximab, statins, and cyclophosphamide. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Focal Segmental Glomerulosclerosis Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on focal segmental glomerulosclerosis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for focal segmental glomerulosclerosis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The focal segmental glomerulosclerosis drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Losmapimod; SHP-627; Sparsentan; TM-5484; Other Types
- 2) By Treatment: Corticosteroids; Immunosuppressive Drugs; Angiotensin Converting Enzymes (ACE) Inhibitors; A.R. Blockers; Diuretics; Other Treatments
- 3) By Route of Administration: Oral; Parenteral
- 4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
- Companies Mentioned: Pfizer Inc.; Johnson and Johnson Ltd.; F. Hoffmann-La Roche AG; Bayer AG; Novartis AG
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Focal Segmental Glomerulosclerosis Drugs Market Characteristics
3. Focal Segmental Glomerulosclerosis Drugs Market Trends And Strategies
4. Focal Segmental Glomerulosclerosis Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Focal Segmental Glomerulosclerosis Drugs Growth Analysis And Strategic Analysis Framework
- 5.1. Global Focal Segmental Glomerulosclerosis Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Focal Segmental Glomerulosclerosis Drugs Market Growth Rate Analysis
- 5.4. Global Focal Segmental Glomerulosclerosis Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Focal Segmental Glomerulosclerosis Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Focal Segmental Glomerulosclerosis Drugs Total Addressable Market (TAM)
6. Focal Segmental Glomerulosclerosis Drugs Market Segmentation
- 6.1. Global Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Losmapimod
- SHP-627
- Sparsentan
- TM-5484
- Other Types
- 6.2. Global Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Corticosteroids
- Immunosuppressive Drugs
- Angiotensin Converting Enzymes (ACE) Inhibitors
- A.R. Blockers
- Diuretics
- Other Treatments
- 6.3. Global Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Parenteral
- 6.4. Global Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Homecare
- Specialty Clinics
- Other End Users
7. Focal Segmental Glomerulosclerosis Drugs Market Regional And Country Analysis
- 7.1. Global Focal Segmental Glomerulosclerosis Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Focal Segmental Glomerulosclerosis Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Focal Segmental Glomerulosclerosis Drugs Market
- 8.1. Asia-Pacific Focal Segmental Glomerulosclerosis Drugs Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Focal Segmental Glomerulosclerosis Drugs Market
- 9.1. China Focal Segmental Glomerulosclerosis Drugs Market Overview
- 9.2. China Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Focal Segmental Glomerulosclerosis Drugs Market
- 10.1. India Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Focal Segmental Glomerulosclerosis Drugs Market
- 11.1. Japan Focal Segmental Glomerulosclerosis Drugs Market Overview
- 11.2. Japan Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Focal Segmental Glomerulosclerosis Drugs Market
- 12.1. Australia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Focal Segmental Glomerulosclerosis Drugs Market
- 13.1. Indonesia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Focal Segmental Glomerulosclerosis Drugs Market
- 14.1. South Korea Focal Segmental Glomerulosclerosis Drugs Market Overview
- 14.2. South Korea Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Focal Segmental Glomerulosclerosis Drugs Market
- 15.1. Western Europe Focal Segmental Glomerulosclerosis Drugs Market Overview
- 15.2. Western Europe Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Focal Segmental Glomerulosclerosis Drugs Market
- 16.1. UK Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Focal Segmental Glomerulosclerosis Drugs Market
- 17.1. Germany Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Focal Segmental Glomerulosclerosis Drugs Market
- 18.1. France Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Focal Segmental Glomerulosclerosis Drugs Market
- 19.1. Italy Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Focal Segmental Glomerulosclerosis Drugs Market
- 20.1. Spain Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Focal Segmental Glomerulosclerosis Drugs Market
- 21.1. Eastern Europe Focal Segmental Glomerulosclerosis Drugs Market Overview
- 21.2. Eastern Europe Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Focal Segmental Glomerulosclerosis Drugs Market
- 22.1. Russia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Focal Segmental Glomerulosclerosis Drugs Market
- 23.1. North America Focal Segmental Glomerulosclerosis Drugs Market Overview
- 23.2. North America Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Focal Segmental Glomerulosclerosis Drugs Market
- 24.1. USA Focal Segmental Glomerulosclerosis Drugs Market Overview
- 24.2. USA Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Focal Segmental Glomerulosclerosis Drugs Market
- 25.1. Canada Focal Segmental Glomerulosclerosis Drugs Market Overview
- 25.2. Canada Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Focal Segmental Glomerulosclerosis Drugs Market
- 26.1. South America Focal Segmental Glomerulosclerosis Drugs Market Overview
- 26.2. South America Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Focal Segmental Glomerulosclerosis Drugs Market
- 27.1. Brazil Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Focal Segmental Glomerulosclerosis Drugs Market
- 28.1. Middle East Focal Segmental Glomerulosclerosis Drugs Market Overview
- 28.2. Middle East Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Focal Segmental Glomerulosclerosis Drugs Market
- 29.1. Africa Focal Segmental Glomerulosclerosis Drugs Market Overview
- 29.2. Africa Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Focal Segmental Glomerulosclerosis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Focal Segmental Glomerulosclerosis Drugs Market Competitive Landscape And Company Profiles
- 30.1. Focal Segmental Glomerulosclerosis Drugs Market Competitive Landscape
- 30.2. Focal Segmental Glomerulosclerosis Drugs Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson and Johnson Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
31. Focal Segmental Glomerulosclerosis Drugs Market Other Major And Innovative Companies
- 31.1. Sanofi S.A.
- 31.2. Bristol Myers Squibb Company
- 31.3. AstraZeneca Plc
- 31.4. Fresenius Kabi Ltd.
- 31.5. GSK Plc
- 31.6. Medtronic Plc.
- 31.7. Takeda Pharmaceutical Company Limited
- 31.8. Eli Lilly and Company
- 31.9. Astellas Pharma Inc.
- 31.10. Otsuka Pharmaceutical Co. Ltd.
- 31.11. Mylan N.V.
- 31.12. B. Braun Melsungen AG
- 31.13. Hikma Pharmaceuticals PLC
- 31.14. Alexion Pharmaceuticals
- 31.15. Wockhardt
32. Global Focal Segmental Glomerulosclerosis Drugs Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Focal Segmental Glomerulosclerosis Drugs Market
34. Recent Developments In The Focal Segmental Glomerulosclerosis Drugs Market
35. Focal Segmental Glomerulosclerosis Drugs Market High Potential Countries, Segments and Strategies
- 35.1 Focal Segmental Glomerulosclerosis Drugs Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Focal Segmental Glomerulosclerosis Drugs Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Focal Segmental Glomerulosclerosis Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
